• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1999-2006 年美国医疗保险受益妇女乳腺癌骨转移和骨骼相关事件后的死亡率:一项基于人群的分析。

Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.

机构信息

School of Public Health, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35294-0022, USA.

出版信息

Breast Cancer Res Treat. 2012 Jan;131(1):231-8. doi: 10.1007/s10549-011-1721-x. Epub 2011 Aug 13.

DOI:10.1007/s10549-011-1721-x
PMID:21842243
Abstract

The aim of the study is to quantify the impact of bone metastasis and skeletal-related events (SREs) on mortality in older breast cancer patients. Using the linked Surveillance, Epidemiology and End Results-Medicare database, we identified women aged 65 years or older diagnosed with breast cancer between July 1, 1999 and December 31, 2005 and followed them to determine deaths occurring through December 31, 2006. We classified patients as having possible bone metastasis and SREs using discharge diagnoses from inpatient claims and diagnoses paired with procedure codes from outpatient claims. We used Cox regression to estimate mortality hazards ratios (HR) among women with bone metastasis with or without SRE, compared with women without bone metastasis. Among 98,260 women with breast cancer (median follow-up, 3.3 years), 7,189 (7.3%) had bone metastasis either at breast cancer diagnosis (1.5%) or during follow-up (5.8%). SREs occurred in 3,319 (46%) of women with bone metastasis. HRs for risk of death were 4.9 (95% CI 4.7-5.1) and 6.2 (95% CI 5.9-6.5), respectively, for women with bone metastasis but no SRE and for women with bone metastasis plus SRE, compared with women without bone metastasis. In analyses restricted to women with bone metastasis, the adjusted HR was 1.5 (95% CI 1.4-1.6) for women with bone metastasis plus SRE, compared with women with bone metastasis but without SRE. Having a bone metastasis, as indicated by Medicare claims, was associated strongly with mortality among women with breast cancer. This association was stronger for bone metastasis complicated by SRE than for bone metastasis without SRE.

摘要

本研究旨在量化骨转移和骨骼相关事件(SREs)对老年乳腺癌患者死亡率的影响。我们使用链接的监测、流行病学和最终结果-医疗保险数据库,确定了 1999 年 7 月 1 日至 2005 年 12 月 31 日期间年龄在 65 岁或以上被诊断患有乳腺癌的女性,并对她们进行随访,以确定截至 2006 年 12 月 31 日发生的死亡情况。我们通过住院患者的出院诊断和门诊患者的诊断与程序代码配对,将患者分为可能发生骨转移和 SREs 的患者。我们使用 Cox 回归来估计有或没有 SRE 的骨转移患者与没有骨转移的患者的死亡率风险比(HR)。在 98260 名患有乳腺癌的女性中(中位随访时间为 3.3 年),7189 名(7.3%)女性在乳腺癌诊断时(1.5%)或随访期间(5.8%)发生骨转移。3319 名(46%)有骨转移的女性发生了 SREs。与没有骨转移的女性相比,无 SRE 的骨转移女性和有骨转移加 SRE 的女性的死亡风险 HR 分别为 4.9(95%CI 4.7-5.1)和 6.2(95%CI 5.9-6.5)。在仅限于有骨转移的女性的分析中,与有骨转移但无 SRE 的女性相比,有骨转移加 SRE 的女性的调整后 HR 为 1.5(95%CI 1.4-1.6)。医疗保险索赔显示的骨转移与乳腺癌女性的死亡率密切相关。这种相关性对于伴有 SRE 的骨转移比不伴有 SRE 的骨转移更强。

相似文献

1
Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.1999-2006 年美国医疗保险受益妇女乳腺癌骨转移和骨骼相关事件后的死亡率:一项基于人群的分析。
Breast Cancer Res Treat. 2012 Jan;131(1):231-8. doi: 10.1007/s10549-011-1721-x. Epub 2011 Aug 13.
2
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.前列腺癌男性患者发生骨转移和骨骼相关事件后的死亡率:1999-2006 年美国医疗保险受益人的基于人群的分析。
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):177-83. doi: 10.1038/pcan.2011.7. Epub 2011 Mar 15.
3
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.回顾性数据库分析唑来膦酸在管理式医疗计划中乳腺癌伴骨转移女性骨骼相关事件和死亡率中的作用。
J Med Econ. 2012;15(1):175-84. doi: 10.3111/13696998.2011.632044. Epub 2011 Nov 8.
4
Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.65岁及以上肺癌患者骨转移和骨相关事件后的死亡率:基于美国医疗保险受益人的人群分析,1999 - 2006年
Lung India. 2013 Jan;30(1):20-6. doi: 10.4103/0970-2113.106127.
5
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.对典型临床实践中所见的乳腺癌骨转移患者骨骼并发症对总医疗费用影响的回顾性研究。
J Support Oncol. 2006 Jul-Aug;4(7):341-7.
6
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.患有前列腺癌骨转移的医疗保险参保者中骨相关事件的临床和经济影响。
Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.
7
Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).丹麦(1999-2007 年)基于人群的队列研究:乳腺癌伴骨转移和骨骼相关事件患者的生存情况。
Breast Cancer Res Treat. 2011 Sep;129(2):495-503. doi: 10.1007/s10549-011-1475-5. Epub 2011 Apr 2.
8
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.在患有乳腺癌骨转移的日本女性中,与安慰剂相比,唑来膦酸显著降低骨骼并发症:一项随机、安慰剂对照试验。
J Clin Oncol. 2005 May 20;23(15):3314-21. doi: 10.1200/JCO.2005.05.116. Epub 2005 Feb 28.
9
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.乳腺癌辅助化疗期间使用粒细胞集落刺激因子后发生急性髓系白血病或骨髓增生异常综合征。
J Natl Cancer Inst. 2007 Feb 7;99(3):196-205. doi: 10.1093/jnci/djk028.
10
Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.肺癌患者的骨转移、骨相关事件及死亡率:一项基于丹麦人群的队列研究。
Lung Cancer. 2014 Nov;86(2):247-54. doi: 10.1016/j.lungcan.2014.08.022. Epub 2014 Sep 10.

引用本文的文献

1
Bone Targeted Parathyroid Hormone Antagonists for Prevention of Breast Cancer Bone Metastases.用于预防乳腺癌骨转移的骨靶向甲状旁腺激素拮抗剂
Cancers (Basel). 2025 Sep 8;17(17):2933. doi: 10.3390/cancers17172933.
2
Acute toxicological evaluation of bone-targeted parathyroid hormone-related peptide (PTHrP) antagonist to inhibit breast cancer metastases to bone.骨靶向甲状旁腺激素相关肽(PTHrP)拮抗剂抑制乳腺癌骨转移的急性毒理学评价
Toxicol Rep. 2025 Jul 12;15:102085. doi: 10.1016/j.toxrep.2025.102085. eCollection 2025 Dec.
3
Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification.
早期乳腺癌中HER2低表达的研究:预后意义及与年龄相关的预后分层
Cancer Med. 2025 Feb;14(4):e70637. doi: 10.1002/cam4.70637.
4
An integrated analysis of bulk and single-cell sequencing data reveals that EMP1/COL3A1 fibroblasts contribute to the bone metastasis process in breast, prostate, and renal cancers.对 bulk 和单细胞测序数据的综合分析揭示,EMP1/COL3A1 成纤维细胞有助于乳腺癌、前列腺癌和肾癌的骨转移过程。
Front Immunol. 2023 Dec 19;14:1313536. doi: 10.3389/fimmu.2023.1313536. eCollection 2023.
5
Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskeletal events?骨转移乳腺癌患者的转移瘤体积与骨骼和骨骼外事件的数量是否相关?
Jt Dis Relat Surg. 2024 Jan 1;35(1):105-111. doi: 10.52312/jdrs.2023.1333. Epub 2023 Nov 2.
6
Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study.常见实体瘤初诊时骨转移的流行率和预后:一项基于人群的研究。
BMJ Open. 2023 Oct 21;13(10):e069908. doi: 10.1136/bmjopen-2022-069908.
7
Assessment of Bone Health Awareness and Education in Breast Cancer Patients with Bone Metastasis in the USA.评估美国乳腺癌伴骨转移患者的骨健康意识和教育。
J Cancer Educ. 2023 Oct;38(5):1522-1530. doi: 10.1007/s13187-023-02293-w. Epub 2023 Apr 28.
8
Metastasis of breast cancer to bones alters the tumor immune microenvironment.乳腺癌骨转移改变了肿瘤免疫微环境。
Eur J Med Res. 2023 Mar 13;28(1):119. doi: 10.1186/s40001-023-01083-w.
9
Validation of Algorithms to Identify Bone Metastases Using Administrative Claims Data in a Japanese Hospital.使用日本一家医院的行政索赔数据验证识别骨转移的算法
Drugs Real World Outcomes. 2023 Jun;10(2):187-194. doi: 10.1007/s40801-022-00347-x. Epub 2023 Jan 18.
10
Non-cancer Causes of Death Following Initial Synchronous Bone Metastasis in Cancer Patients.癌症患者初次发生同步骨转移后的非癌症死亡原因
Front Med (Lausanne). 2022 Jun 2;9:899544. doi: 10.3389/fmed.2022.899544. eCollection 2022.